Adenosine receptor antagonists as immunotherapeutic agents for cancer

腺苷受体拮抗剂作为癌症免疫治疗剂

• 批准号: nhmrc : 1062580
• 负责人: A/Pr Phillip Darcy
• 金额: $ 37.06万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/adenosine-receptor-antagonists-agents-cancer/455006
• 关键词: Adenosine; receptor; antagonists; immunotherapeutic; agents

We have shown that drugs that block immunosuppressive adenosine receptors can improve anti-tumour immune responses and consequently enhance the effectiveness of chemotherapy. These drugs are already known to be well-tolerated in humans and so have great potential for clinical development. We propose to determine the therapeutic response achieved with these drugs in combination with established cancer treatments involving radiotherapy and immune based therapies.

我们已经证明，阻断免疫抑制腺苷受体的药物可以改善抗肿瘤免疫反应，从而增强化疗的效果。已知这些药物在人类中具有良好的耐受性，因此具有巨大的临床开发潜力。我们建议确定这些药物与现有的癌症治疗（包括放射疗法和免疫疗法）相结合所达到的治疗反应。